Literature DB >> 25462595

810nm near-infrared light offers neuroprotection and improves locomotor activity in MPTP-treated mice.

Florian Reinhart1, Nabil El Massri2, Fannie Darlot3, Napoleon Torres4, Daniel M Johnstone5, Claude Chabrol6, Thomas Costecalde7, Jonathan Stone8, John Mitrofanis9, Alim-Louis Benabid10, Cécile Moro11.   

Abstract

We explored whether 810nm near-infrared light (NIr) offered neuroprotection and/or improvement in locomotor activity in an acute 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated mouse model of Parkinson's disease. Mice received MPTP and 810nm NIr treatments, or not, and were tested for locomotive activity in an open-field test. Thereafter, brains were aldehyde-fixed and processed for tyrosine hydroxylase immunohistochemistry. Our results showed that MPTP-treated mice that were irradiated with 810nm NIr had both greater locomotor activity (∼40%) and number of dopaminergic cells (∼20%) than those that were not. In summary, 810nm (as with 670nm) NIr offered neuroprotection and improved locomotor activity in MPTP-treated mice.
Copyright © 2014 Elsevier Ireland Ltd and the Japan Neuroscience Society. All rights reserved.

Entities:  

Keywords:  Neuroprotection; Substantia nigra; Tyrosine hydroxylase

Mesh:

Substances:

Year:  2014        PMID: 25462595     DOI: 10.1016/j.neures.2014.11.005

Source DB:  PubMed          Journal:  Neurosci Res        ISSN: 0168-0102            Impact factor:   2.904


  17 in total

Review 1.  Brain Photobiomodulation Therapy: a Narrative Review.

Authors:  Farzad Salehpour; Javad Mahmoudi; Farzin Kamari; Saeed Sadigh-Eteghad; Seyed Hossein Rasta; Michael R Hamblin
Journal:  Mol Neurobiol       Date:  2018-01-11       Impact factor: 5.590

2.  Photobiomodulation-induced changes in a monkey model of Parkinson's disease: changes in tyrosine hydroxylase cells and GDNF expression in the striatum.

Authors:  Nabil El Massri; Ana P Lemgruber; Isobel J Rowe; Cécile Moro; Napoleon Torres; Florian Reinhart; Claude Chabrol; Alim-Louis Benabid; John Mitrofanis
Journal:  Exp Brain Res       Date:  2017-03-15       Impact factor: 1.972

Review 3.  Photobiomodulation as a treatment for neurodegenerative disorders: current and future trends.

Authors:  Namgue Hong
Journal:  Biomed Eng Lett       Date:  2019-06-12

Review 4.  Therapies for Parkinson's diseases: alternatives to current pharmacological interventions.

Authors:  Song Li; Jie Dong; Cheng Cheng; Weidong Le
Journal:  J Neural Transm (Vienna)       Date:  2016-08-11       Impact factor: 3.575

Review 5.  Current application and future directions of photobiomodulation in central nervous diseases.

Authors:  Muyue Yang; Zhen Yang; Pu Wang; Zhihui Sun
Journal:  Neural Regen Res       Date:  2021-06       Impact factor: 5.135

6.  Near-infrared light (670 nm) reduces MPTP-induced parkinsonism within a broad therapeutic time window.

Authors:  Florian Reinhart; Nabil El Massri; Daniel M Johnstone; Jonathan Stone; John Mitrofanis; Alim-Louis Benabid; Cécile Moro
Journal:  Exp Brain Res       Date:  2016-02-15       Impact factor: 2.064

7.  Significant Improvement in Cognition in Mild to Moderately Severe Dementia Cases Treated with Transcranial Plus Intranasal Photobiomodulation: Case Series Report.

Authors:  Anita E Saltmarche; Margaret A Naeser; Kai Fai Ho; Michael R Hamblin; Lew Lim
Journal:  Photomed Laser Surg       Date:  2017-02-10       Impact factor: 2.796

Review 8.  Current Pharmaceutical Treatments and Alternative Therapies of Parkinson's Disease.

Authors:  Jie Dong; Yanhua Cui; Song Li; Weidong Le
Journal:  Curr Neuropharmacol       Date:  2016       Impact factor: 7.363

Review 9.  Neuroprotective Effects Against POCD by Photobiomodulation: Evidence from Assembly/Disassembly of the Cytoskeleton.

Authors:  Ann D Liebert; Roberta T Chow; Brian T Bicknell; Euahna Varigos
Journal:  J Exp Neurosci       Date:  2016-02-01

Review 10.  Turning On Lights to Stop Neurodegeneration: The Potential of Near Infrared Light Therapy in Alzheimer's and Parkinson's Disease.

Authors:  Daniel M Johnstone; Cécile Moro; Jonathan Stone; Alim-Louis Benabid; John Mitrofanis
Journal:  Front Neurosci       Date:  2016-01-11       Impact factor: 4.677

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.